The 503B Loophole Closes: Why the FDA is Moving to Exclude GLP-1s from Bulk Compounding
On April 30, 2026, the FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. As legitimate compounding pathways narrow, independent analytical testing becomes the only reliable defense against substandard supply.